Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Population Pharmacokinetics and Optimization of the Dosing Regimen of Digoxin in Adult Patients

Toshiaki Komatsu, Mami Morita, Futaba Miyaji, Takayuki Inomata, Junya Ako and Koichiro Atsuda

Background Lanoxin is wide prescribed for the treatment of symptom cardiopathy and cardiac arrhythmia. healing drug observation of Lanoxin is suggested due to its slender healing vary. previous research have reportable many equations and nomograms to alternate physicians to work out the desirable dose of Lanoxin for character sufferers. moreover, populace pharmacokinetic information imply that clearance of Lanoxin is encouraged by demographic variables like age, overall weight, and blood serum creatinine stages. however, population materia medica has now not been studied up to now to judge the impact of concomitant administration of medication like amiodarone, verapamil, and tolvaptan on relative Lanoxin clearance. currently, the therapeutic range for Lanoxin in patients with cardiopathy with a traditional sinus rhythm has been revised to a low and slender vary (0.5-zero.eight ng/mL) supported the findings from the digitalis investigation cluster trial. for the duration of this look at, we generally tend to aimed to investigate the populace materia medica of Lanoxin in the presence of concomitant management of various medication. what's extra, we generally tend to decided preliminary dosing regimens to attain concentrations (0.five-zero.8 ng/mL) in step with our population pharmacokinetic information.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado.